Industry executive to lead emerging Australian biopharma AdAlta

Latest News

Australian biopharmaceutical company AdAlta (ASX:1AD) has appointed a senior and experienced industry executive as its new CEO and managing director.

Dr Tim Oldham's experience spans life sciences strategy and business development, commercial and manufacturing operations and alliance management across Europe, Asia and Australia, with a particular focus on biologic, cellular therapies and pharmaceuticals.

In his most recent role, Dr Oldham was the executive leader at Tijan Ventures, providing strategic planning, capital raising, interim executive management and board leadership to a company focused on immunotherapy, cell and gene therapy.

He has previously served as CEO and managing director of Cell Therapies, a leading Asia Pacific contract development and manufacturing organisation for cellular therapies, president of Asia Pacific for Hospira and a variety of senior management roles with Mayne Pharma in Europe prior to its acquisition by Hospira.

"We are delighted to have someone of Tim’s calibre and experience join AdAlta as our new Chief Executive Officer,” said executive chairman, Paul MacLeman.

“Tim brings a diverse and international skillset, but his biologics and commercialisation expertise will be invaluable as we approach a number of important milestones: non human primate preclinical results, the commencement of phase I human trials for AD-214, and the furthering of late-stage partnering discussions for AdAlta’s i-body platform. The Board looks forward to working with him to continue to progress our strategy around these value-driving activities.”

Dr Oldham is also a board member of BioMelbourne Network.